Cytodyn Inc (CYDY)

[Cindylou822]

You are arguing that it's saline solution. It's not. It has shown efficacy in several indication. Madrigal just PR'ed clinically relevant response in NASH. They never used the word statistically.

Leronlimab has shown efficacy in HIV, cancer and early signs in NASH. Saline solution doesn't do that.

And, the safety of the compound for s important. Madrigal also indicated in their PR that they needed so many patients on their study to show their drug is safe. Leronlimab has that in multiple indications in very sick populations. NASH studies are difficult to enroll. Having that safety data can only help.

Your arguments are not relevant to the multiple indications leronlimab has. Cancer and NASH especially would be most attractive to potential partners. The safety data should cut down on the time a partner would need to wait to find out how their investment pans out. It's a difficult indication and that is important.